PEPetra J. M. Elders

Petra J. M. Elders

*This is an algorithmically generated author record based on publicly available information.

Petra J. M. Elders has a total of 558 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Process evaluation of the INTENSE study aimed at improving adherence to oral diabetes and/or hypertension medication in people with type 2 diabetes

    by Marlous Langendoen-Gort, Debi Bhattacharya, Hiyam Al-Jabr, Maartje de Wit, Jacqueline G Hugtenburg, Andrew Farmer, Petra Jm Elders, Femke Rutters

    Introduction: The aim of this study was to evaluate the implementation and the potential of a pharmacist-led personalised intervention program, aimed at improving medication adherence to oral diabetes and/or hypertension medication in people with type 2 diabetes (T2D), to be normalized in daily clinical practice. Material and methods: A parallel-group randomized controlled trial (RCT) was conducted in 68 participants in 26 community pharmacies from the Netherlands (NL) and the UK. This manuscript reports on a multi-method process analysis that was performed parallel to the six-month follow-up of the RCT. Quantitative data, including data from the data management platform, were analyzed with descriptive statistics. Qualitative data were collected via semi-structured interviews with purposively selected pharmacists (high/low numbers of recruited participants) and participants (high/low satisfaction) and audio-recorded consultations between pharmacists and participants. Semi-structured interviews were analyzed using the Framework approach, the Medical Research Council process evaluation framework of complex interventions and Extended Normalization Process Theory. Audio-recorded consultations were analyzed using the OPTION-12 scale and a self-composed checklist. Results: The fidelity and dose of the intervention program were assessed as high. Consultations were conducted according to the study protocol. Participants’ satisfaction with the intervention modules varied, but overall, participants were satisfied with the clinical medication review, medication schedule, medication dispensing system and referral to their primary care physician. The reach was assessed as low, resulting from selection procedure’ difficulties and only 68 out of the intended 300 participants were recruited. Selection procedure adaptations did not increase the reach. The potential of the intervention program was assessed as high, since pharmacists valued the development of a medication adherence intervention. Contribution was also assessed as high, because of collective action from stakeholders. Finally, capability and capacity were assessed as moderate, due to material resource and workability barriers. Discussion: In its current form the pharmacist-led personalised intervention program cannot be implemented and normalized into daily care. In this process evaluation several barriers including the selection procedure and recruitment of participants have been identified that need to be resolved before the effectiveness of this personalised intervention program can be re-evaluated. Future research should therefore focus on alternative methods for engaging people with T2D with insufficient medication adherence in medication adherence interventions.


  • Open Access

    Effectiveness of a pharmacy-led personalised intervention program aimed at improving adherence to oral diabetes and/or hypertension medication in people with type 2 diabetes

    by Marlous Langendoen-Gort, Sharon Remmelzwaal, Femke Rutters, Hiyam Al-Jabr, Maartje de Wit, Debi Bhattacharya, Jacqueline G Hugtenburg, Andrew Farmer, Petra Jm Elders

    Aims/hypothesis: To evaluate the effectiveness of a personalised intervention program aimed at improving medication adherence in people with type 2 diabetes who are non-adherent to oral diabetes and/or hypertension medication, compared to usual care including access to a diabetes website, after a six-month follow-up. Methods: Parallel-group randomised controlled trial with six-month follow-up conducted in community pharmacies in the Netherlands and United Kingdom. People with type 2 diabetes, 35-75 years and non-adherent to oral diabetes and/or hypertension medication were recruited. The intervention group received the personalised intervention program and the control group received usual care and an informative diabetes website. The primary outcome was medication adherence measured by telephone pill count and secondary outcomes were self-reported medication adherence, systolic blood pressure and HbA1c level. Linear regression analysis and longitudinal mixed model analysis were performed to assess intervention effectiveness. Results: The study population comprised 68 participants, 66.2% men with a median age of 65.0 [Q1 to Q3 59.3 to 71.0] years. Linear regression analysis for the primary outcome medication adherence showed no significant effect of the intervention (B −0.014, 95% CI −0.17 to 0.14). In addition, no significant differences were found between the intervention and control group for self-reported medication adherence (OR 3.18, 95% CI 0.89 to 11.37) and systolic blood pressure (B −1.41, 95% CI −9.64 to 6.83). Finally, the intervention group did not show better HbA1c levels compared to the control group (B 0.68, 95% CI 0.44 to 0.92). Conclusions/interpretation: We did not observe a statistically significant difference, nor a clinically point estimate of difference, in medication adherence between the intervention and control group of a personalised intervention program aimed at improving medication adherence in people with type 2 diabetes who are non-adherent to oral diabetes and/or hypertension medication after six-months follow-up. We therefore do not recommend implementation of the intervention program in daily practice. Trial registry number: Registered in the Dutch Trial Register (Trial NL8747) and ISRCTN Registry ( ISRCTN36009809 ). Social media post: No effect of a personalised intervention program was observed on medication adherence in people with type 2 diabetes. Future studies should first focus on alternative recruitment methods for non-adherent people with type 2 diabetes, before the effectiveness of the intervention can be re-evaluated in a larger study sample. Research in context: What is already known about this subject?: Medication non-adherence is a common health problem in people with type 2 diabetes. Most medication adherence interventions showed small and inconsistent effects, potentially because interventions are not personalised to the needs of participants. What is the key question?: What is the effect of a personalised intervention program aimed at improving medication adherence in people with type 2 diabetes who are non-adherent to oral diabetes and/or hypertension medication, compared to usual care including access to a publicly available diabetes website, after six months of follow-up? What are the new findings?: No effect was observed of the personalised intervention program on medication adherence measured with a telephone pill count. No effect was observed of the personalised intervention program on self-reported medication adherence and systolic blood pressure. The intervention group did not show better HbA1c levels compared to the control group. Recruitment of participants was challenging and as such we were unable to achieve the intended study sample. How might this impact on clinical practice in the foreseeable future?: We currently do not recommend implementation of the personalised intervention program in routine practice. Further work is first needed to establish alternative recruitment methods for non-adherent people with type 2 diabetes, before the effectiveness of the intervention can be re-evaluated in a larger study sample.

  • Open Access

    Interventions to reduce diabetes-related distress among adults with type 1 or type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials

    by Samantha B. J. Schipper, Thomas Karagiannis, Francesco Zaccardi, Sharon Remmelzwaal, Marieke Blom, Noa Dagan, Linda J. Schoonmade, Miranda Langendam, Martin M. Jensen, Walther Jensen, et al.

    Aims/hypothesis: Diabetes distress refers to the emotional and psychological burden specifically associated with living with and managing diabetes. We aimed to systematically identify, summarise and critically appraise the available evidence from RCTs assessing the efficacy of interventions for reducing diabetes distress among adults with type 1 or type 2 diabetes. Methods: We searched PubMed, the Cochrane Library, APA PsycInfo and CINAHL from inception until 23 September 2024. Studies were eligible if they were RCTs conducted in adults (aged ≥18 years) with type 1 or type 2 diabetes in which the effect of an active intervention on diabetes distress was recorded as a primary or a secondary outcome. Studies with combined populations (e.g. children plus adults) where no separate results were reported for adults were excluded. When possible, we performed a random-effects meta-analysis of the standardised mean difference (SMD) of the endpoint, diabetes distress, measured with a validated questionnaire. We conducted subgroup analyses based on baseline diabetes distress level, intervention delivery method, risk of bias assessment (using the Cochrane RoB2 tool) and trial duration. We used GRADE methodology to assess the certainty of evidence. Results: We included 248 trials, with 59 trials reporting on psychological interventions, 68 on psychoeducational interventions and 121 on miscellaneous interventions (non-psychological or non-psychoeducational, i.e. education without a psychological component, peer support without a psychological component, devices, telehealth, health behaviours and a heterogeneous group of other interventions). In total, 52 trials included participants with type 1 diabetes (including two during pregnancy), 160 included participants with type 2 diabetes, and 36 included mixed/undefined populations of adults with diabetes. The total sample size was 55,497 participants (range 12–4034). The analysed trials were judged to have either some concerns for risk of bias (94 trials) or a high risk of bias (71 trials). Compared with usual care, psychological interventions reduced diabetes distress in adults with type 1 diabetes (SMD −0.22 [95% CI −0.35, −0.08]; N =16; GRADE = low) and type 2 diabetes (SMD −0.31 [95% CI −0.50, −0.13]; N =21; GRADE = very low). Additionally, continuous glucose monitoring (CGM) or intermittently scanned glucose monitoring reduced diabetes distress in adults with type 1 diabetes, compared with standard blood glucose measurement (SMD −0.26 [95% CI −0.41, −0.11]; N =6; GRADE = moderate), while educational interventions reduced diabetes distress in adults with type 2 diabetes, compared with usual care (SMD −0.34 [95% CI −0.56, −0.11]; N =3; GRADE = low). Other comparisons, including those of psychological, psychoeducational, peer support, educational and device-based interventions with various active control interventions or usual care, did not show statistically significant effects. The results did not differ meaningfully across predefined subgroups. The certainty of evidence as assessed by GRADE methodology was moderate, low or very low in two, five and seven comparisons, respectively. No meta-analyses could be conducted for telehealth, health behaviours and the assorted mixed interventions due to heterogeneity or an insufficient number of studies. Conclusions/interpretation: Psychological interventions reduced diabetes distress among adults with type 1 diabetes and those with type 2 diabetes, while devices reduced diabetes distress in adults with type 1 diabetes and education reduced diabetes distress in adults with type 2 diabetes. Most other interventions showed little or no clear effect. Funding: European Association for the Study of Diabetes. Registration: PROSPERO registration no. CRD42024598512.


  • Open Access

    Interventions to reduce diabetes-related distress among adults with type 1 and type 2 diabetes: protocol for a systematic review and meta-analysis

    by Samantha B. J. Schipper, Sharon Remmelzwaal, Marieke T. Blom, Lenka Groeneveld, Miranda Langendam, Petra J. M. Elders, Martin M. Jensen, Walther Jensen, Norbert Hermanns, Richard I. G. Holt, et al.

  • Open Access

    A narrative review of what cohorts have taught us and how they have laid the foundation for much of our understanding of type 2 diabetes

    by Sun H. Kim, Ipsa Arora, Charles Agyemang, Ranjit M. Anjana, Bjørn Olav Åsvold, Marieke Blom, Shilpa N. Bhupathiraju, Amélie Bonnefond, Juliana C. N. Chan, Timothy M. E. Davis, et al.

  • Open Access

    The Feasibility of an App-Based Worksite Health Promotion Program to Improve Mental Well-Being and Work-Related Vitality in University Hospital Workers: Process and Preliminary Effect Evaluation Study

    by Sanne H M Kremers, Joline W J Beulens, Cédric N H Middel, Petra J M Elders, Allard J van der Beek, Femke Rutters

    Background: University hospital employees face role-specific stressors that can impair mental well-being and work-related vitality. While worksite health promotion programs show potential for improving mental well-being by targeting lifestyle behaviors, most target single professions or hospital subunits, and evidence for mental well-being and work-related vitality remains mixed. Mobile apps offer unique advantages for delivering such worksite health promotion programs hospital-wide. However, accessible interventions tailored to a diverse workforce are lacking. Objective: This study aimed to investigate the feasibility of an app-based worksite health promotion program (the Recharge360 program [The Recharge Company]) targeting multiple lifestyle behaviors, including a team-based competition element, for improving mental well-being and work-related vitality of hospital employees over a 5-month follow-up period by evaluating two objectives: (1) the implementation process of the program, and (2) the preliminary effects of the program on mental well-being and work-related vitality. Methods: We included 532 employees (mean age 43, SD 12 y; n=482, 91% women; n=480, 90% highly educated) from a university hospital in Amsterdam, the Netherlands. The study had a single-arm, longitudinal pretest-posttest design lasting 5 months, during which employees participated in the 5-day Recharge360 program (Recharge week) 3 times—in weeks 1, 9, and 17. At baseline (T0) and after each Recharge week (T1-T3), we assessed mental well-being, work ability, need for recovery, and task performance. The process was evaluated by assessing recruitment, attrition, and survey completion rates, and the degree of participation. Preliminary effects were evaluated by linear mixed model regression analyses to assess changes in mental well-being and work-related vitality between baseline and follow-up. Results: Recruitment appeared feasible, but attrition rates were high (up to 70% in the final Recharge week), and the degree of participation decreased over time. We showed statistically significant, albeit small, increases in well-being at T3 (unstandardized β coefficient=2.08, 95% CI 0.33-3.84), with progressively larger improvements in the analyses among those who started at least 1, 2, and all 3 Recharge weeks (unstandardized β coefficient=3.27, 95% CI 1.09-5.45). Results for work-related vitality were mixed. The need for recovery remained unchanged, task performance increased slightly at T3 (unstandardized β coefficient=0.16, 95% CI 0.07-0.24). Work ability showed a small, but statistically significant, decline across follow-up (unstandardized β coefficient=−0.46, 95% CI −0.64 to −0.29). Conclusions: This app-based worksite health promotion program might be feasible to implement in a university hospital setting and shows potential to slightly improve mental well-being, but primarily for a selective group of highly educated, health-conscious women. While these findings support further investigation in a randomized controlled trial in similar university hospital settings, they also highlight the need for more participatory study designs to improve the tailoring of program components and engagement of underrepresented groups, as well as for a supportive culture and population-based approaches at the organizational level.

  • Open Access

    Replication of 10 novel loci involved in human plasma protein N-glycosylation using MALDI-MS and UHPLC-FD data

    by Anna Timoshchuk, Annemieke Naber, Roderick Slieker, Anna Soplenkova, Denis Maslov, Nadezhda A Potapova, Simone Nicolardi, P J M Elders, Eric J G Sijbrands, Sodbo Sharapov, et al.

    N-glycans are essential components of glycoproteins, influencing their properties and functions. While biochemical pathways of glycosylation are well-characterized, their genetic regulation remains poorly understood. This study utilizes matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) and ultra-high performance liquid chromatography-fluorescence detection (UHPLC-FD) to strengthen replication and further characterize previously identified genome-wide association signals for the total human plasma N-glycome (TPNG). Univariate and multivariate genetic association meta-analyses involved 3385 samples across 143 N-glycome traits from the Hoorn Diabetes Care System and DiaGene cohorts as well as 3224 samples across 117 N-glycome traits from TwinsUK, CEDAR, QMDiab and SABRE cohorts. We successfully replicated ten previously identified but not replicated glycosylation quantitative trait loci (glyQTLs) and prioritized five high-confidence putative causal genes, including the glycosyltransferase MGAT4B and inflammation-related genes – C3 and FCGR2B. The linkage-specific sialic acid derivatization in MALDI-MS enabled delineation of genetic effects on α2,3- and α2,6-sialylation. Mass spectrometry analysis, triggered and guided by association to a locus containing B3GAT1 glucuronosyltransferase, provided evidence for hexuronic acid-containing glycans in human blood plasma. These findings advance our understanding of the genetic regulation of protein N-glycosylation and highlight the complementarity of different analytical approaches in glycomics research.

  • Top Cited Papers

    Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX

    by John A. Kanis, Eugene V. McCloskey, Helena Johansson, Enwu Liu, Kristina E. Åkesson, Fred A. Anderson, Rafael Azagra-Ledesma, Cecilie L. Bager, Charlotte Beaudart, Heike A. Bischoff-Ferrari, et al.

    Summary The relationship between bone mineral density (BMD) at the femoral neck and fracture risk was determined in a meta-analysis of primary data of 307205 men and women from 53 cohort studies. Low BMD was an important predictor of fracture risk, particularly for hip fracture. Introduction This study aimed to quantify the relationship between DXA-measured femoral neck BMD and fracture risk and examine the effect of age, sex, time since measurement, and initial BMD value on fracture risk, with a view to updating FRAX®. Methods We studied 307,205 men and women from within 53 predominately population-based cohorts followed up for an average of 8.7 years and a total of 2,683,185 person-years. The association of BMD and fracture risk was examined using a Poisson model in each cohort separately by sex. Results were expressed as a gradient of risk (GR, hazard ratio/standard deviation decrease in BMD). The different studies were then merged using weighted coefficients. Results Most hip fractures arose in men and women with low bone mass or osteoporosis at baseline (73% and 92%, respectively) as was also the case for MOF (65% and 85%, respectively). BMD at the femoral neck strongly predicted hip fractures both in men and women with a similar gradient of risk and absolute risk at any given T-score. At the age of 65 years, the GR was 2.73 (95% CI = 2.29–3.26) in men and 2.61 (95% CI = 2.34–2.92) in women. However, the magnitude of association was significantly dependent on age, with a higher gradient of risk at younger ages. For example, at age 50 years, the GR was 3.49 (95% CI 2.51–4.84) in men and decreased to 2.14 (1.96–2.34) at age 80 years. The change in GR with age was slightly less marked in women (3.23 [2.75–3.80] and 2.11 [1.99–2.44], respectively). The GR for major osteoporotic fracture (MOF) remained unchanged with age (p = 0.12 for women and p = 0.89 for men). A significant decrease in GR for hip fracture was observed with increasing duration of follow-up, but the magnitude of the effect was modest compared with the effect of age. For other fracture outcomes, including non-hip major osteoporotic fracture, the gradient of risk was lower than for hip fracture. Conclusions Femoral neck BMD is a risk factor for fracture of substantial importance, particularly for future hip fracture. The lower magnitude of association at older age is consistent with other non-skeletal factors contributing to hip fracture risk with advancing age. Its validation on an international basis supports its use in case finding strategies. Its use should, however, take account of the variations in predictive value of BMD with age, sex, length of follow-up, and BMD.


  • Open Access

    Statistical analysis plan of the study titled “A deprescribing programme aimed to optimize blood glucose-lowering medication in older people with type 2 diabetes mellitus — the OMED2 study: a randomized controlled trial”

    by Charlotte Andriessen, Peter P. Harms, Marieke T. Blom, Anna W. de Boer, G. Ardine de Wit, Ron Herings, Rob J. van Marum, Jacqueline G. Hugtenburg, Daniël van Raalte, Liselotte van Bloemendaal, et al.

    Background: The OMED2 ( Optimization of Medication in Elderly with Diabetes ) study addresses the effect and implementation of integrating a deprescribing programme (DPP) in general practice. The aim of the DPP is to reduce glucose-lowering medication (SU/insulin) in overtreated older patients. The protocol for this study has been published previously. This statistical analysis plan (SAP) contains a more elaborate outline of the (statistical) methods we plan to use for data analysis. Methods: The OMED2 study is a randomized mixed-methods study with a 2-year follow-up period that compares the effect of the implementation of a DPP in general practice to regular care (control). In this SAP, we report on the (statistical) approaches that we plan to use to address the study objectives. The main objective of the OMED2 study is to examine the effect of the implementation of the DPP on diabetes complications, whereby the total number of diabetes complications related to undertreatment and overtreatment will be summed. Generalized linear mixed models with a Poisson distribution and the DPP as the main determinant will be used to test whether the total number of diabetes complications occurring from the start of the 2-year follow-up until the end of follow-up differs between intervention and control. The incident rate of the number of diabetes complications will be calculated to correct for possible differences in follow-up duration. The model will also include a random effect variable to allow for possible clustering effects by general practice. We will perform intention-to-treat analyses, which include all patients eligible for deprescribing, as well as per protocol analyses, which omit patients who were not deprescribed in the intervention arm. Additionally, approaches to study the implementation of the DPP and the cost-effectiveness of the implementation are outlined in the SAP. Trial registration: ISRCTN Registry ISRCTN50008265. Registered on 1 November 2024.

  • Open Access

    Calciprotein crystallization time (T50) and its association with surrogate cardiovascular disease risk markers in individuals with type 2 diabetes mellitus: the cross-sectional EARLY-HFpEF study

    by R. Meer, A. G. Hoek, E. Dal Canto, T. Doesburg, A. Pasch, M. G. Vervloet, P. A. de Jong, P. J. M. Elders, J. W. J. Beulens

    Background: Heart failure and peripheral artery disease (PAD) are the two most common cardiovascular diseases (CVD) in individuals with type 2 diabetes mellitus (T2DM). The T 50 calciprotein crystallization test measures the transformation of calciprotein particles type 1 (CPP1) into CPP2 in vitro and has been introduced as a low-cost biomarker for arterial calcification and CVD risk. We aimed to investigate the association between T 50 and (1) heart failure with preserved ejection fraction (HFpEF), (2) ankle-brachial index (ABI) as measure of PAD, (3) pulse wave velocity (PWV) as measure of central arterial stiffness and (4) arterial calcification in individuals with T2DM. Methods: Cross-sectional data was used of 771 individuals with T2DM (64% men, 67 [63–71] years). T 50 was measured using nephelometry on non-fasting serum samples. Presence of HFpEF was assessed with echocardiography based on current guidelines. ABI was categorized as ≤ 0.9 (PAD), 0.9–1.4 (normal) and ≥ 1.4 (high). Central arterial stiffness was measured using carotid-femoral PWV. Lower-extremity and coronary calcification were measured using computed tomography and quantified using Agatston scores categorized into zero (reference category) and tertiles > 0. Multivariable-adjusted Poisson, multinomial and linear regression analyses were used to study the associations with aforementioned surrogate CVD risk markers. Results: Mean T 50 was 355 ± 55 min. HFpEF and PAD were present in 36.6% and 5.8% of the cohort, respectively. Mean cfPWV was 12.9 ± 2.5 m/s. Median calcification scores in the coronary arteries and lower-extremities were 315 [40–1246] and 791 [64–3820] Agatston units, respectively. Every 60-min decrease in T 50 , indicating higher calcification risk, was associated with increased coronary arterial calcification (e.g. highest tertile OR = 1.63 [1.15–2.30], p = 0.006), but not with lower-extremity arterial calcification (e.g. highest tertile OR = 1.28 [0.96–1.69], p = 0.088). Moreover, T 50 ≤ 330 min versus T 50 ≥ 390 min was associated with PAD (OR = 3.04 [1.03–8.94], p = 0.044). Finally, every 60-min decrease in T 50 was not associated with neither HFpEF (RR = 1.02 [0.90–1.17], p = 0.736) nor cfPWV (β = − 0.08 [ − 0.26–0.10], p = 0.398). Conclusion: Low T 50 was associated with increased risks of coronary arterial calcification and PAD (measured by ABI ≤ 0.9) in individuals with T2DM, but not with HFpEF, central arterial stiffness and lower-extremity arterial calcification. Further research is warranted to evaluate the additive value of T 50 in CVD risk stratification in clinical care.